647 related articles for article (PubMed ID: 26700119)
1. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
2. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
3. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
4. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
6. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
7. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
9. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
[TBL] [Abstract][Full Text] [Related]
10. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
11. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
12. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
[TBL] [Abstract][Full Text] [Related]
13. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
14. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
20. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]